T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...

AmplifyBio and Xcell Biosciences have announced a strategic collaboration to advance the manufacturing process for engineered T-cell receptor (TCR) therapies. The alliance will focus on optimising ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...

Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the ...

Medigene continuously strengthens and expands its patent portfolio by developing new 3S TCRs, integrating advanced technologies, and extending its existing patents to new regions. The Company now owns ...

Unlike CAR-T cell therapy, which recognizes surface antigens, TCR therapy is engineered to identify intracellular antigens presented by major histocompatibility complex (MHC) molecules ...

Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that members of the company’s management team will ...